The novel adipocytokine visfatin exerts direct cardioprotective effects

Journal of Cellular and Molecular Medicine

Volumn 12, Issue 4, 2008, Pages 1395-1403

  Lim, Shiang Y ^a   Davidson, Sean M ^a   Paramanathan, Ajeev J ^a   Smith, Christopher C T ^a   Yellon, Derek M ^a   Hausenloy, Derek J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cardioprotection; Ischaemia; Reperfusion; Visfatin

Indexed keywords

1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ADIPOCYTOKINE; ANDROSTANE DERIVATIVE; CARDIOTONIC AGENT; CARRIER PROTEIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NITRILE; OXYGEN; PHOSPHATIDYLINOSITOL 3 KINASE; WORTMANNIN;

ANIMAL; APOPTOSIS; ARTICLE; C57BL MOUSE; CELL SURVIVAL; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; HEART INFARCTION; HEART MUSCLE CELL; HEMODYNAMICS; MALE; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; REPERFUSION INJURY; TIME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADIPOKINES; ANDROSTADIENES; ANIMALS; APOPTOSIS; BUTADIENES; CARDIOTONIC AGENTS; CELL SURVIVAL; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEMODYNAMICS; MALE; MAP KINASE KINASE KINASES; MICE; MICE, INBRED C57BL; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NITRILES; OXYGEN; TIME FACTORS;

MURINAE; MUS;

EID: 49549089810     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00332.x     Document Type: Article

References (40)

1. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001 24 : 683 9.
2. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004 110 : 1245 50.
3. Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care. 2005 28 : 2508 13.
4. Zeller M, Steg PG, Ravisy J, Laurent Y, Janin-Manificat L, L'Huillier I, Beer JC, Oudot A, Rioufol G, Makki H, Farnier M, Rochette L, Verges B, Cottin Y. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med. 2005 165 : 1192 8.
5. Clavijo LC, Pinto TL, Kuchulakanti PK, Torguson R, Chu WW, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R. Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications. Cardiovasc Revasc Med. 2006 7 : 7 11.
6. Celik T, Turhan H, Kursaklioglu H, Iyisoy A, Yuksel UC, Ozmen N, Isik E. Impact of metabolic syndrome on myocardial perfusion grade after primary percutaneous coronary intervention in patients with acute ST elevation myocardial infarction. Coron Artery Dis. 2006 17 : 339 43.
7. Matsuzawa Y. Therapy insight: adipocy-tokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2006 3 : 35 42.
8. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, Walsh K. Adiponectin protects against myocardial ischemia -reperfusion injury through AMPK- and COX-2 dependent mechanisms. Nat Med. 2005 11 : 1096 103.
9. Smith CC, Mocanu MM, Davidson SM, Wynne AM, Simpkin JC, Yellon DM. Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects. Br J Pharmacol. 2006 149 : 5 13.
10. Simpkin JC, Yellon DM, Davidson SM, Lim SY, Wynne AM, Smith CC. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol. 2007 102 : 518 28.
11. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005 307 : 426 30.
12. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC. Pre-B cell colony-enhancing factor inhibits neu-trophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest. 2004 113 : 1318 27.
13. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK) pathway. Cardiovasc Res. 2004 61 : 448 60.
14. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev. 2007 12 : 217 34.
15. Davidson SM, Hausenloy D, Duchen MR, Yellon DM. Signalling via the reper-fusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardio-protection. Int J Biochem Cell Biol. 2006 38 : 414 9.
16. Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol. 2003 35 : 339 41.
17. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J. 1995 307 : 93 8.
18. Bae SK, Kim SR, Kim JG, Kim JY, Koo TH, Jang HO, Yun I, Yoo MA, Bae MK. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett. 2006 580 : 4105 13.
19. Segawa K, Fukuhara A, Hosogai N, Morita K, Okuno Y, Tanaka M, Nakagawa Y, Kihara S, Funahashi T, Komuro R, Matsuda M, Shimomura I. Visfatin in adipocytes is upregulated by hypoxia through HIF1alpha-dependent mechanism. Biochem Biophys Res Commun. 2006 349 : 875 82.
20. Lim SY, Davidson SM, Hausenloy DJ, Yellon DM. Preconditioning and postcon-ditioning: the essential role of the mito-chondrial permeability transition pore. Cardiovasc Res. 2007 75 : 530 5.
21. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Retraction. Science. 2007 318 : 565.
22. Haider DG, Holzer G, Schaller G, Weghuber D, Widhahn K, Wagner O, Kapiotis S, Wolzt M. The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr. 2006 43 : 548 9.
23. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mel-litus. J Clin Endocrinol Metab. 2006 91 : 295 9.
24. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, Erdem G, Gok M, Bingol N, Kilic S, Ozgurtas T, Bingol S. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract. 2007 76 : 24 9.
25. Krzyzanowska K, Mittermayer F, Krugluger W, Kopp H P, Schernthaner G. Increase in visfatin after weight loss induced by gastroplastic surgery. Obesity. 2006 14 : 1886 9.
26. Haider DG, Mittermayer F, Schaller G, Artwohl M, Baumgartner-Parzer SM, Prager G, Roden M, Wolzt M. Free fatty acids normalize a rosiglitazone-induced visfatin release. Am J Physiol Endocrinol Metab. 2006 291 : E885 90.
27. Chan TF, Chen YL, Lee CH, Chou FH, Wu LC, Jong SB, Tsai EM. Decreased plasma visfatin concentrations in women with ges-tational diabetes mellitus. J Soc Gynecol Investig. 2006 13 : 364 7.
28. Haider DG, Pleiner J, Francesconi M, Wiesinger GF, Muller M, Wolzt M. Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes. J Clin Endocrinol Metab. 2006 91 : 4702 4.
29. Manco M, Fernandez-Real JM, Equitani F, Vendrell J, Valera Mora ME, Nanni G, Tondolo V, Calvani M, Ricart W, Castagneto M, Mingrone G. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab. 2007 92 : 483 90.
30. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspll G, Vettor R. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006 91 : 3165 70.
31. Samal B, Sun YH, Steams G, Xie CS, Suggs S, Mcniece I. Cloning and characterization of the cDNA-encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994 14 : 1431 7.
32. Ye SQ, Zhang LQ, Adyshev D, Usatyuk PV, Garcia AN, Lavoie TL, Verin AD, Natarajan V, Garcia JG. Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation. Microvasc Res. 2005 70 : 142 51.
33. Garcia JG, Moreno VL. Genomic insights into acute inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol. 2006 291 : L1113 7.
34. Ognjanovic S, Bao S, Yamamoto SY, Garibay-Tupas J, Samal B, Bryant-Greenwood GD. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol. 2001 26 : 107 17.
35. Van Der Veer E, Nong Z, O'Neil C, Urquhart B, Freeman D, Pickering JG. Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res. 2005 97 : 25 34.
36. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyl-transferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol. 2002 32 : 3225 34.
37. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003 63 : 7436 42.
38. Khan JA, Tao X, Tong L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol. 2006 13 : 582 8.
39. Kim SR, Bae SK, Choi KS, Park SY, Jun HO, Lee JY, Jang HO, Yun I, Yoon KH, Kim YJ, Yoo MA, Kim KW, Bae MK. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun. 2007 357 : 150 6.
40. Dahl TB, Yndestad A, Skjelland M, Oie E, Dahl A, Michelsen A, Damas JK, Tunheim SH, Ueland T, Smith C, Bendz B, Tonstad S, Gullestad L, Froland SS, Krohg-Sorensen K, Russell D, Aukrust P, Halvorsen B. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007 115 : 972 80.